241 related articles for article (PubMed ID: 3265693)
1. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
Kanellos J; MacKenzie IF; Pietersz GA
Immunol Cell Biol; 1988; 66 ( Pt 5-6)():403-15. PubMed ID: 3265693
[TBL] [Abstract][Full Text] [Related]
2. Intratumour therapy of solid tumours with ricin-antibody conjugates.
Kanellos J; McKenzie IF; Pietersz GA
Immunol Cell Biol; 1989 Apr; 67 ( Pt 2)():89-99. PubMed ID: 2786496
[TBL] [Abstract][Full Text] [Related]
3. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumour activity of aminopterin-monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate-monoclonal antibody conjugates.
Kanellos J; Pietersz GA; Cunningham Z; McKenzie IF
Immunol Cell Biol; 1987 Dec; 65 ( Pt 6)():483-93. PubMed ID: 3502340
[TBL] [Abstract][Full Text] [Related]
5. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
Smyth MJ; Pietersz GA; McKenzie IF
Cancer Res; 1988 Jul; 48(13):3607-12. PubMed ID: 3259905
[TBL] [Abstract][Full Text] [Related]
6. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
Lynch TJ
Chest; 1993 Apr; 103(4 Suppl):436S-439S. PubMed ID: 8384975
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
9. Blocked and not blocked whole-ricin-antibody immunotoxins: intraperitoneal therapy of human tumour xenografted in nude mice.
Brusa P; Pietribiasi F; Bussolati G; Dosio F; Arione R; Comoglio PM; Prat M; Cattel L
Cancer Immunol Immunother; 1989; 29(3):185-92. PubMed ID: 2659170
[TBL] [Abstract][Full Text] [Related]
10. Immunotoxins constructed with anti-CD25 monoclonal antibodies and deglycosylated ricin A-chain have potent anti-tumour effects against human Hodgkin cells in vitro and solid Hodgkin tumours in mice.
Engert A; Martin G; Amlot P; Wijdenes J; Diehl V; Thorpe P
Int J Cancer; 1991 Sep; 49(3):450-6. PubMed ID: 1917143
[TBL] [Abstract][Full Text] [Related]
11. The chronic lymphocytic leukemia antigen (cCLLa) as immunotherapy target: pharmacokinetics and biodistribution of two divalent, ricin-based immunotoxins in xenografted athymic mice.
Faguet GB; Agee JF
Leuk Lymphoma; 1997 May; 25(5-6):509-20. PubMed ID: 9250822
[TBL] [Abstract][Full Text] [Related]
12. Blockade of the galactose-binding sites of ricin by its linkage to antibody. Specific cytotoxic effects of the conjugates.
Thorpe PE; Ross WC; Brown AN; Myers CD; Cumber AJ; Foxwell BM; Forrester JT
Eur J Biochem; 1984 Apr; 140(1):63-71. PubMed ID: 6608447
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
14. Whole ricin and recombinant ricin A chain idiotype-specific immunotoxins for therapy of the guinea pig L2C B cell leukemia.
Gregg EO; Bridges SH; Youle RJ; Longo DL; Houston LL; Glennie MJ; Stevenson FK; Green I
J Immunol; 1987 Jun; 138(12):4502-8. PubMed ID: 3495593
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of growth of human tumor xenografts in athymic mice treated with ricin toxin A chain-monoclonal antibody 791T/36 conjugates.
Byers VS; Pimm MV; Scannon PJ; Pawluczyk I; Baldwin RW
Cancer Res; 1987 Oct; 47(19):5042-6. PubMed ID: 3497715
[TBL] [Abstract][Full Text] [Related]
16. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
Blakey DC; Watson GJ; Knowles PP; Thorpe PE
Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
[TBL] [Abstract][Full Text] [Related]
17. In vivo cytotoxic efficacy of immunotoxins prepared from anti-CD5 antibody linked to ricin A-chain.
Rostaing-Capaillon O; Casellas P
Cancer Immunol Immunother; 1991; 34(1):24-30. PubMed ID: 1722138
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts.
Krauer KG; McKenzie IF; Pietersz GA
Cancer Res; 1992 Jan; 52(1):132-7. PubMed ID: 1530766
[TBL] [Abstract][Full Text] [Related]
19. Recombinant ricin toxin A chain cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin B chain.
Embleton MJ; Charleston A; Robins RA; Pimm MV; Baldwin RW
Br J Cancer; 1991 May; 63(5):670-4. PubMed ID: 2039690
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates.
Fishwild DM; Wu HM; Carroll SF; Bernhard SL
Clin Exp Immunol; 1994 Jul; 97(1):10-8. PubMed ID: 8033405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
